Fig 1.
Study population and number of Health Questionnaires performed.
Table 1.
Patients’ characteristics at their first visit (n = 4,186).
Table 2.
Frequency of side effects reported by PLWH on ART in relation to gender, age, route of transmission, origin, CD4-cell count, missed doses of ART, PROs, time on ART and time since HIV diagnosis (9,137 HQs).
Fig 2.
Frequency of patient-reported side effects on the Health Questionnaire in the InfCareHIV Swedish national registry during 2011–2017.
Fig 3.
Trend analysis of percentage per year of PLWH prescribed efavirenz or dolutegravir, respectively, and percentage of PLWH reporting side effects.
Table 3.
Logistic regression: Determinants for reporting having experienced side effects in 4,186 PLWH based on 9,137 Health Questionnaires from between 2011 and 2017.
Table 4.
Prevalence of prescribed third agent in PLWH experiencing side effects and of prescribed third agent in ART of PLWH who completed the Health Questionnaire during 2011–2017.
Table 5.
Possible adverse events and experiences that participants described as side effects.